Wegovy pill outperforms Lilly oral GLP-1 in cross-trial claim

Novo Nordisk said its oral formulation of Wegovy appeared to outperform Eli Lilly’s oral GLP‑1 candidate on several efficacy metrics in cross‑trial comparisons, a statement aimed at shaping the narrative as both companies push into the oral obesity drug market.

The company highlighted results from the OASIS‑4 programme, reporting about 16.6% average weight loss among adherent participants on oral Wegovy, while published data from Lilly’s clinical programme showed average weight reductions around 12.4% for its highest oral doses in comparable obesity studies. Novo and external observers stressed that differences in trial populations, durations and protocols limit the validity of direct cross‑trial comparisons.

Financial markets reacted to the competing data narratives as investors weighed potential impacts on market share and future sales. Regulatory timelines and U.S. approval status for oral candidates have major commercial implications; attention is focused on how quickly payers will place oral GLP‑1s on formularies and how supply chains will respond to demand.

In the broader context, the GLP‑1 and dual‑agonist race has seen mixed head‑to‑head results in injectable treatments, and the emergence of effective oral agents reshapes access and adherence dynamics. While injectables previously dominated headline efficacy figures in some trials, oral options may alter treatment algorithms if real‑world tolerability and convenience translate to sustained use.

Market analysts note Novo’s messaging is an important commercial maneuver but caution that definitive conclusions require head‑to‑head trials, longer follow‑up and payer decisions. The near‑term outlook will depend on further trial disclosures, regulatory approvals and how physicians and patients weigh efficacy against tolerability and convenience in routine care.